A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Primary Objective
To compare objective response rate, progression free survival, and overall survival between fianlimab + cemiplimab and opdualag in participants with unresectable or metastatic melanoma
Details
Age
Adult
Locations
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital
Principal Investigator
Steven Schuster
Study ID
Protocol Number: 24-1034
More information available at ClinicalTrials.gov: NCT06246916
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers